The Kaplan-Meier analyses unveiled a significant survival benefit of glioma patients with high ACCN2 (P < 0.001, log-rank test; Fig. 10b) or high ACCN3 expression (P = 0.003, log-rank test; Fig. 10c). The gene discussed is ASIC3; the disease is glioma.